Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Starting in 2027, low- and middle-income countries will get a $40 annual HIV prevention injection, lenacapavir, via Indian generics.
Starting in 2027, a twice-yearly HIV prevention injection, lenacapavir, will be available for $40 per year in 120 low- and middle-income countries through Indian generic manufacturers, a dramatic drop from the current U.S. price of about $28,000.
The drug, developed by Gilead and recommended by the WHO, offers up to 100% efficacy and could improve adherence among high-risk groups.
Funded by the Gates Foundation and Unitaid, the initiative aims to expand access by 2027, with South Africa expected to approve it by November 2025.
Experts urge swift domestic rollout in India and broader global licensing to ensure equitable access and reduce new HIV infections.
A partir de 2027, los países de ingresos bajos y medios recibirán una inyección anual de prevención del VIH de 40 dólares, el lenacapavir, a través de genéricos indios.